Lines were then treated with different concentrations of EGFR inhibitors (gefitinib or cetuximab), with or without a MET tyrosine kinase inhibitor (EMD 1214063). Methods: TNBC lines (MDA-MB-468, HCC-1395, and MDA-MB-231), and a hormone receptor-positive breast cancer line (T47D) were stimulated with epidermal growth factor (EGF) and hepatocyte growth factor (HGF). We aimed to study the efficacy of targeting MET in overcoming resistance to EGFR therapy in TNBC cell lines. However, anti-EGFR therapies have not been effective in these patients. File import instruction Abstractīackground: EGFR expression and pathway activation are common in triple-negative breast cancer (TNBC). Select the file that you have just downloaded and select import option Reference Manager (RIS). Available fromĬlick on Go to download the file. cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. Sohn J, Liu S, Parinyanitikul N, Lee J, Hortobagyi GN, Mills GB, Ueno NT, Gonzalez-Angulo AM.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |